↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Rahman Z, Resnick L, Rosenzweig-Lipson SJ, Ring RH,"Methods of treatment using oxytocin receptor agonists", US patent application 2007/0117794, published 24. 05. 2007. , assigned to Wyeth Corp
↑Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G (2008). „Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents”. Progress in Brain Research170: 473–512. DOI:10.1016/S0079-6123(08)00437-8. PMID18655903.
↑Ring RH, Schechter LE, Leonard SK, Dwyer JM, Platt BJ, Graf R, Grauer S, Pulicicchio C, Resnick L, Rahman Z, Sukoff Rizzo SJ, Luo B, Beyer CE, Logue SF, Marquis KL, Hughes ZA, Rosenzweig-Lipson S (July 2009). „Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist”. Neuropharmacology58 (1): 69–77. DOI:10.1016/j.neuropharm.2009.07.016. PMID19615387.